logo-loader

Shield Therapeutics CEO delighted with further positive results from pivotal Feraccru study

Published: 23:28 30 Jan 2019 AEDT

Carl Sterritt, chief executive of Shield Therapeutics PLC (LON:STX), tells Proactive London's Andrew Scott their iron deficiency treatment Feraccru delivered strong benefits for people with kidney-related anaemia in an extended trial.

The 52-week open-label study showed increased haemoglobin levels in both those taking it for the whole period and also in those who switched from the placebo after the first 16-weeks.

Shield Therapeutics: Analysis of data from AEGIS-H2H is strongly supportive...

Proactive Research analyst Emma Ulker says further conclusions from Shield Therapeutics' (LON:STX) analysis of data from the AEGIS-H2H study are strongly supportive of ongoing discussions for the global commercialisation, pricing and reimbursement of Feraccru. She adds that with the analysis...

on 10/8/20